PTEN and p27 expression in mature T-cell and NK-cell neoplasms

References

• Leslie N R, Downes C P. Pten: The down side of PI 3-kinase signaling. Cellular Signaling 2002; 14: 285–295
   PubMed Web of Science ®Google Scholar
• Simpson L, Parson R. PTEN: Life as a tumor suppressor. Exp Cell Res 2001; 264: 29–41
   PubMed Web of Science ®Google Scholar
• Sulis M L, Parson R. PTEN: Form pathology to biology. Trends in Cell Biology 2003; 13: 478–483
   PubMed Web of Science ®Google Scholar
• Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S I, et al. PTEN, a putative protein thyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 1997; 275: 1943–1947
   PubMed Web of Science ®Google Scholar
• Steck P A, Pershouse M A, Jasser S A, Yung W K, Lin H, Ligon A H, et al. İdentification of a candifate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997; 15: 356–362
   PubMed Web of Science ®Google Scholar
• Li D M, Sun H. TEP1, encoded by a candidate tumor suppressor locus, is a novel protein thyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 1997; 57: 2124–2129
   PubMed Web of Science ®Google Scholar
• Di Cristofano A, Pandolfi P P. The multiple roles of PTEN in tumor suppression. Cell 2000; 100: 387–390
   PubMed Web of Science ®Google Scholar
• Vivanco I, Sawyers C. The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nature Reviews Cancer 2002; 2: 489–501
   PubMed Web of Science ®Google Scholar
• Massague J. G1 cell-cycle control and cancer. Nature 2004; 432: 298–306
   PubMed Web of Science ®Google Scholar
• Brazil D P, Yang Z -Z, Hemmings B A. Advances in protein kinase B signalling: AKTion on multiple fronts. Trends in Biochemical Sciences 2004; 29: 233–242
   PubMed Web of Science ®Google Scholar
• Ricardo V L, Erickson L A, Jin L, Kulig E, Qian X, Cheville J C, et al. p27kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999; 154: 313–323
   PubMed Web of Science ®Google Scholar
• Krystal G. Lipid phosphatases in the immune system. Sem Immunol 2000; 12: 397–403
   PubMed Web of Science ®Google Scholar
• Ott V L, Cambier J C. Introduction: multifaceted roles of lipids and their catabolites in immune cell signaling. Sem Immunol 2002; 14: 1–6
   PubMed Web of Science ®Google Scholar
• Schmidt-Weber C B, Wohlfahrt J G, Akdis C A, Blaser K. The phosphatydylinositol phosphatase PTEN is under control of costimulation and regulates proliferation in human T cells. Eur J Immunol 2002; 32: 1196–1204
   PubMed Web of Science ®Google Scholar
• Wang X, Gjörloff-Wingren A, Saxena M, Pathan N, Reed J C, Mustelin T. The tumor suppressor PTEN regulates T cell survival and antigen receptor signaling by acting as a phosphatidylinositol 3-phosphatase. J Immunol 2000; 164: 1934–1936
   PubMed Web of Science ®Google Scholar
• Shan X, Czar M, Bunnell S C, Liu P, Liu Y, Schwartzberg P L. Deficiency of PTEN in Jurkat T cells causes constitutive localization of Itk to the plasma membrane and hyper responsiveness to CD3 stimulation. Mol Cell Biol 2000; 20: 6945–6957
   PubMed Web of Science ®Google Scholar
• Suzuki A, Yamaguchi M T, Ohteki T, Sasaki T, Kaisho T, Kimura Y, et al. T cell specific loss of pten leads to defects in central and peripheral tolerance. Immunity 2001; 14: 523–534
   PubMed Web of Science ®Google Scholar
• Dahia P LM, Aguiar R CT, Alberta J, Kum J B, Caron S, Sill H, et al. PTEN is inversely correlated with the cell survival factor AKT/PKB and is inactivated via multiple mechanisms in haematological malignancies. Hum Mol Genet 1999; 8: 185–193
   PubMed Web of Science ®Google Scholar
• Gottschalk A R, Basila D, Wong M, Dean N M, Brandts C H, Stokoe D, Haas-Kogan D A. p27Kip1 is required for PTEN-induced G1 growth arrest. Cancer Res 2001; 61: 2105–2111
   PubMed Web of Science ®Google Scholar
• Cheney I W, Neuteboom S TC, Vaillancourt M -T, Ramachandra M, Bookstein R. Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes. Cancer Res 1999; 59: 2318–2323
   PubMed Web of Science ®Google Scholar
• Bruni P, Boccia A, Baldassarre G, Trapasso F, Santoro M, Chüappetta G, et al. PTEN expression is reduced in a subset of sporadic thyroid carcinoms: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27Kip1. Oncogene 2000; 19: 3126–3155
   PubMed Web of Science ®Google Scholar
• Jaffe E S, Harris N L, Stein H, Vardiman J W. WHO Pathology and genetics: Tumours of hematopoietic and lymphoid tissues. 2001; 12–13, Lyon: IARC Press
   Google Scholar
• Sansal I, Sellers W R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954–2963
   PubMed Web of Science ®Google Scholar
• Ginn-Pease M E, Eng C. Increased nuclear phosphate and tensin homologue deleted on chromosome 10 is associated with G0-G1 in MCF-7 cells. Cancer Res 2003; 63: 282–286
   PubMed Web of Science ®Google Scholar
• Sakai A, Thieblemont C, Wellmann A, Jaffe E S, Raffeld M. PTEN gene alterations in lymphoid neoplasms. Blood 1998; 92: 3410–3415
   PubMed Web of Science ®Google Scholar
• Scarisbrick J J, Woolford A J, Russel-Jones R, Whittaker S J. Loss of heterozygosity on 10q and microsatellite instability in advanced stages of primary cutaneous T-cell lymphoma and possible association with homozygous deletion of PTEN. Blood 2000; 95: 2937–2942
   PubMed Web of Science ®Google Scholar
• Li J, Simpson L, Takahashi M, Miliaresis C, Myers M P, Tonks N, Parsons R. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res 1998; 58: 5667–5672
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Nakamura N, Vazquez F, Batt D B, Perera S, Roberts T M, Sellers W R. Regulation of G1 progression by the PTEN tumor suppressor protein is linked to inhibition of the phosphatidylinositol 3-Kinase/AKT pathway. Proc Natl Acad Sci USA 1999; 96: 2110–2115
   PubMed Web of Science ®Google Scholar
• Quintanilla-Martinez L, Thieblemont C, Fend F, Kumar S, Pinyol M, Campo E, et al. Mantle cell lymphomas lack expression of p27Kip1, a cyclin-dependent kinase inhibitor. Am J Pathol 1998; 15: 3175–3182
   Google Scholar
• Sanchez-Beato M, Camacho F J, Martinez-Montero J C, Saez A I, Villuendas R, Sanchez-Verde L, et al. Anomalous high p27/KIP1 expression in a subset of aggressive B-cell lymphomas is associated with cyclin D3 overexpression: p27/KIP1-cyclin D3 colocalization in tumor cells. Blood, 94: 765–772
   PubMed Web of Science ®Google Scholar
• Morosetti R, Kawamata N, Gombart A F, Miller C W, Hatta Y, Hirama T, et al. Alterations of the p27KIP1 gene in non-Hodgkin's lymphomas and adult T-cell leukemia/lymphoma. Blood 1995; 86: 1924–1930
   PubMed Web of Science ®Google Scholar
• Erlanson M, Portin C, Linderholm B, Lindh J, Roos G, Landberg G. Expression of cyclin E and the cyclin-dependent kinase inhibitor p27 in malignant lymphomas-prognostic implications. Blood 1998; 92: 770–777
   PubMed Web of Science ®Google Scholar
• Moller M B, Skjodt K, Mortensen L S, Pedersen N T. Clinical significance of cyclin-dependent kinase inhibitor p27Kip1 expression and proliferation in non-Hodgkin's lymphoma: independent prognostic value of p27Kip1. Brit J Haemato 1999; 105: 730–736
   PubMed Web of Science ®Google Scholar
• Kuefer M U, Look A T, Pulford K, Behm F G, Pattengale P K, Mason D Y, Morris S W. Retrovirus-mediated gene transfer of NPM-ALK causes lymphoid malignancy in mice. Blood 1997; 90: 2901–2910
   PubMed Web of Science ®Google Scholar
• Bai R Y, Dieter P, Peschel C, Morris S W, Duyster J. Nucleophosmin-anaplastic lymphoma kinase of large-cell anaplastic lymphoma is a constitutively active tyrosine kinase that utilizes phospholipase C-gamma to mediate its mitogenicity. Mol Cell Biol 1998; 18: 6951–6961
   PubMed Web of Science ®Google Scholar
• Bai R Y, Ouyang T, Miething C, Morris S W, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidylinositol 3-kinase-Akt antiapoptotic signaling pathway. Blood 2000; 96: 4319–4327
   PubMed Web of Science ®Google Scholar
• Slupianek A, Nieborowska-Skorska M, Hoser G, Morrione A, Majewski M, Xue L, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001; 61: 2194–2199
   PubMed Web of Science ®Google Scholar
• Slupianek A, Skorski T. NPM/ALK downregulates p27Kip1 in a PI-3K-dependent manner. Exp Hematol 2004; 32: 1265–1271
   PubMed Web of Science ®Google Scholar
• Rassidakis G Z, Feretzaki M, Atwell C, Grammatikakis I, Lin Q, Lai R, et al. Inhibition of Akt increases p27Kip1 levels and induces cell cycle arrest in anaplastic large cell lymphoma. Blood 2005; 105: 827–829
   PubMed Web of Science ®Google Scholar
• Rassidakis G Z, Claret F X, Lai R, Zhang Q, Sarris A H, McDonnell T J, Medeiros L J. Expression of p27(Kip1) and c-Jun activation binding protein 1 are inversely correlated in systemic anaplastic large cell lymphoma. Clin Cancer Res 2003; 9: 1121–1128
   PubMed Web of Science ®Google Scholar